

## MicroPort Scientific Corporation Announced the Annual Report 2011

On April 20<sup>th</sup>, 2012, MicroPort Scientific Corporation announced its <annual report 2011>, which has already been published on the website of MicroPort ([www.microport.com.cn](http://www.microport.com.cn)) and Hong Kong Exchanges ([www.hkexnews.hk](http://www.hkexnews.hk)).

Before the announcement of the report, an earnings call was held on March 19<sup>th</sup>, 2012. Mr. Hongbin Sun, CFO, presented details of the annual results and answered questions from the participants. According to the report, the profit for the year ended 31 December, 2011 was 321 million RMB which represented a 33.6% increase YOY; and the revenue amounted to 840 million RMB with an increase of 15.4% YOY.

## MicroPort Orthopedics Receives FDA 510k Approval for Reindeer™ Locking Plate System

On March 29<sup>th</sup>, 2012, MicroPort Orthopedics Co., Ltd. announced the FDA 510k approval for its Reindeer™ Locking Plate System with registration Num. K112798, which is the first FDA approval product for MicroPort.

Based on the BO (Bio-logical osteosynthesis) principle, the newly approved locking plate system, combined with locking plate and locking bone screws (锁定接骨螺钉), was designed for internal fixation

**Disclaimer:** The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

of fracture for extremities (四肢骨), which possesses unprecedented advantage for fixing complicated fracture and further potential applications. Since this is the first FDA approval for MicroPort orthopedics product following its CE certification, it has created favorable conditions for MicroPort to further explore the international market.

## MicroPort Receives SFDA Approval for GnRH Infusion Pump

On March 23<sup>th</sup>, 2012, MicroPort announced that the SFDA has approved its La Fenice® GnRH Infusion Pump, which is the first pulsatile GnRH infusion pump in China jointly developed by MicroPort Lifesciences Co., Ltd. and Shanghai Ruijin Hospital.

GnRH Infusion Pump is designed to meet the needs of Chinese physicians and patients for the treatment of Idiopathic Hypogonadotropic Hypogonadism (IHH) which is also known as Kallmann Syndrome. Equipped with pulse infusion via micro pump technology, GnRH infusion pump stimulates hypophysis to excrete Follicle-Stimulating Hormone (FSH)/ luteinizing hormone (LH) by simulating pulse excretion of human gonadotropin-releasing hormone (GnRH) in order to make patients recover from abnormally physiological regulated function.

Kallmann syndrome is a genetic disorder marked

by anosmia and hypogonadism. Abnormalities in various genes may cause a defect in the hypothalamus, causing a deficiency of gonadotropin-releasing hormone (GnRH); this in turn causes deficiency in FSH and LH levels. Kallmann syndrome is also called hypothalamic hypogonadism. GnRH pulse infusion have a significant effect on maintaining and increasing in secondary sex characters, a progressive improvement of deficiency of grown-up Growth Hormone (GH) and bone mineral density (BMD), makes a contribution to regain fertility, and reduces the risk of cardiovascular-related adverse events, which is the most ideal treatment for such disease in these days.



## EasyLoop™ Diagnostic Catheter Approved by SFDA

On April 6<sup>th</sup>, 2012, MicroPort EP MedTech Co., Ltd. announced the SFDA approval of EasyLoop™ Circumferential Pulmonary Vein Diagnostic Catheter. EasyLoop™ is indispensable in AF (Atrial Fibrillation)

procedure. The circular portion of the catheter is delivered into each pulmonary vein to collect the local electrical signals. The catheter is used along with the 3D mapping system and ablation catheter to complete the pulmonary vein isolation.

EasyLoop™ is the third certificated EP product of MicroPort following FireMagic® and EasyFinder™. In addition, it is the first product for the procedure of complex arrhythmias treatment from MicroPort EP MedTech Co., Ltd.



## MicroPort Established Aspiration Scholarship for Shanghai Jiao Tong University

Recently, MicroPort made a 250,000RMB donation to the School of Biomedical Engineering, Shanghai Jiao Tong University to establish MicroPort Aspiration Scholarship. It aims at promoting the education development and encouraging the students in the biomedical engineering field.

MicroPort Aspiration Scholarship will be mainly used for offering financial supporting to excellent undergraduate and sponsoring short-term overseas exchange study. Establishment of the scholarships provides a significant opportunity for promoting admission and education for Biomedical Engineering students, and enhance close cooperation between the university and the company.

**Disclaimer:** The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

More Details on: [www.microport.com.cn](http://www.microport.com.cn)

Email: [ir@microport.com](mailto:ir@microport.com)  
Tel (021) 38954600  
Fax (021) 50801305

## Introduction of IHH and GnRH Infusion Pump

IHH (Idiopathic Hypogonadotropic Hypogonadism) is characterized by low gonadotropin levels, absence of LH and FSH pulses, low sex steroid hormone levels, delay in or complete failure to undergo puberty, and finally result in infertility. By definition, either anosmia (lack of sense of smell) or severe hyposmia is present in patients with Kallmann syndrome.

## Connection between Puberty and IHH Pathogenesis


Puberty is initiated by hormonal signals from the brain to the gonads and marked by the pulsatile GnRH, with a 60-90 minutes release cycle which may increase gradually with age until the peak pulses become regular on a daily basis.

Low-frequency GnRH pulses lead to FSH release, whereas high-frequency GnRH pulses stimulate LH release. The function of LH is to stimulate the production of sex hormones, from the ovaries in women and from the testicles, or testes, in men. And the FSH controls sperm and ovarian follicle production.

Delay of the puberty with deficient secondary sex characters can result in infertility.

## The best IHH Therapy

IHH can be treated by GnRH, gonadotropin or testosterone therapy. Pulsatile GnRH therapy is the best for those with a hypothalamic failure.



## Therapeutic Effect

The LH and FSH levels would rise significantly with pulse waves in the pulse injection three days after the GnRH therapy.

The patient would begin to undergo puberty after 12 weeks ( $LH/FSH > 0.7$ ). And the sexual characteristic would appear with regular and steady releasing of LH and FSH.

After 24 weeks of treatment, the testicular volume and sperm count would increase with the improvement of sexual desire for male.

The first menstruation (menarche) would occur 100 days after the treatment for female, and the menstrual periods gradually become normal.

During the period of 6-9 months, the obvious curative effect would become prominent through the change of secondary sex characters of the patients.

Currently, some of our patients who had undergone the treatment have successfully become pregnant already..